prikaz prve stranice dokumenta Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
  Download
PDF 305.16 KB
Scientific paper - Review paper
Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
Acta clinica Croatica, 63. (2024), 2; 436-449. https://doi.org/10.20471/acc.2024.63.02.22
Jančuljak, Davor; Petravić, Damir; Mahović Lakušić, Darija; Lovrenčić-Huzjan, Arijana; Bačić Baronica, Koraljka; Bosnar Puretić, Marijana; Hucika, Zlatko; Titlić, Marina; Popović, Zvonimir; Tomić, Zoran; Stojić, Maristela; Bašić Kes, Vanja

Cite this document

Jančuljak, D., Petravić, D., Mahović Lakušić, D., Lovrenčić Huzjan, A., Bačić Baronica, K., Bosnar Puretić, M. ... Bašić Kes, V. (2024). Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab). Acta clinica Croatica, 63.. (2), 436-449. doi: 10.20471/acc.2024.63.02.22

Jančuljak, Davor, et al. "Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)." Acta clinica Croatica, vol. 63., no. 2, 2024, pp. 436-449. https://doi.org/10.20471/acc.2024.63.02.22

Jančuljak, Davor, Damir Petravić, Darija Mahović Lakušić, Arijana Lovrenčić Huzjan, Koraljka Bačić Baronica, Marijana Bosnar Puretić, Zlatko Hucika, et al. "Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)." Acta clinica Croatica 63., no. 2 (2024): 436-449. https://doi.org/10.20471/acc.2024.63.02.22

Jančuljak, D., et al. (2024) 'Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)', Acta clinica Croatica, 63.(2), pp. 436-449. doi: 10.20471/acc.2024.63.02.22

Jančuljak D, Petravić D, Mahović Lakušić D, Lovrenčić Huzjan A, Bačić Baronica K, Bosnar Puretić M, and sur.. Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab). Acta clinica Croatica [Internet]. 2024 [cited 2025 February 27];63.(2):436-449. doi: 10.20471/acc.2024.63.02.22

D. Jančuljak, et al., "Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)", Acta clinica Croatica, vol. 63., no. 2, pp. 436-449, 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:190557. [Accessed: 27 February 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
Title (croatian)Hrvatske smjernice za specifično profilaktičko liječenje migrene monoklonskim protutijelima na peptid povezan s kalcitoninskim genom (CGRP) (eptinezumab, fremanezumab i galkanezumab) i na CGRP receptor (erenumab)
AuthorDavor Jančuljak
AuthorDamir Petravić
AuthorDarija Mahović Lakušić
AuthorArijana Lovrenčić-Huzjan
AuthorKoraljka Bačić Baronica
AuthorMarijana Bosnar Puretić
AuthorZlatko Hucika
AuthorMarina Titlić
AuthorZvonimir Popović
AuthorZoran Tomić
AuthorMaristela Stojić
AuthorVanja Bašić Kes
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Neurology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Calcitonin gene-related peptide (CGRP) plays a key role in the pathophysiology of migraine, acting on CGRP receptors in the trigeminovascular system, causing neurogenic inflammation and vasodilation, and promoting nociception. Four specific monoclonal antibodies targeting CGRP are available for prevention of episodic and chronic migraine in adults with at least four migraine days per month. The aim of these guidelines is to provide evidence-based recommendations for the use of monoclonal antibodies targeting CGRP in migraine prevention in Croatia. The questions were formulated using the Patients, Intervention, Comparison, Outcome (PICO) criteria, with evidencebased answers. To assess the quality of scientific evidence, a review of the literature available in PubMed was performed. Relevant studies were reviewed by the Expert Group of the Headache Section of the Croatian Neurological Society, and served as the basis for formulating the recommendations outlined in these guidelines. We found high quality evidence for good safety and efficacy of anti- CGRP monoclonal antibodies in the preventive treatment of episodic and chronic migraine. These medications may be considered as first-line prophylactic therapy depending on the patient’s history, concomitant diseases, and disease burden. Further real-world studies are needed to elucidate other aspects of their application.
Abstract (croatian)
Peptid povezan s kalcitoninskim genom (CGRP) igra ključnu ulogu u patofiziologiji migrene djelujući na CGRP receptore u trigeminovaskularnom sustavu, time uzrokujući neurogenu upalu i vazodilataciju, uz promociju nocicepcije. Četiri specifična monoklonska protutijela koja djeluju na CGRP su dostupna u profilaksi epizodne i kronične migrene u odraslih osoba s najmanje četiri migrenozna dana na mjesec. Cilj ovih smjernica je pružiti preporuke zasnovane na dokazima za primjenu monoklonskih protutijela koja djeluju na CGRP u prevenciji migrene u Hrvatskoj. Pitanja su formulirana primjenom kriterija PICO (Patients, Intervention, Comparison, Outcome), uz odgovore zasnovane na dokazima. Kako bismo procijenili kvalitetu znanstvenih dokaza pretražili smo literaturu u bazi podataka PubMed. Pronađene relevantne studije analizirala je Stručna skupina Sekcije za glavobolju Hrvatskoga neurološkog društva i služile su kao osnova za oblikovanje preporuka navedenih u ovim smjernicama. Pronašli smo visokokvalitetne dokaze u smislu dobre sigurnosti i učinkovitosti monoklonskih protutijela na CGRP u profilaksi epizodne i kronične migrene. Ovi lijekovi se mogu razmatrati u prvoj liniji profilaktičke terapije, ovisno o bolesnikovoj povijesti bolesti, supostojećim bolestima i opterećenosti bolešću. Daljnje studije u kliničkim uvjetima potrebne su kako bi se rasvijetlili dodatni aspekti njihove primjene.
Keywords (english)
Keywords (croatian)
Languageenglish
Languagecroatian
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleActa clinica Croatica
Numberingvol. 63., no. 2, pp. 436-449
p-ISSN0353-9466
e-ISSN1333-9451
DOIhttps://doi.org/10.20471/acc.2024.63.02.22
URN:NBNurn:nbn:hr:184:190557
Publication2024
Document URLhttps://hrcak.srce.hr/328166
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2025-02-27 14:25:08